Unknown

Dataset Information

0

Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells.


ABSTRACT: In a tumor microenvironment, endothelial cell migration and angiogenesis allow cancer to spread to other organs causing metastasis.  Indeed, a number of molecules that are involved in cytoskeleton re-organization and intracellular signaling have been investigated for their effects on tumor cell growth and metastasis. Alongside that, Amblyomin-X, a recombinant Kunitz-type protein, has been shown to reduce metastasis and tumor growth in in vivo experiments. In the present report, we provide a mechanistic insight to these antitumor effects, this is,  Amblyomin-X modulates Rho-GTPases and uPAR signaling, and reduces the release of MMPs, leading to disruption of the actin cytoskeleton and decreased cell migration of tumor cell lines. Altogether, our data support a role for Amblyomin-X as a novel potential antitumor drug.

Abbreviations

Amb-X: Amblyomin-X; ECGF: endotelial cell growth factor; ECM: extracellular matrix; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HUVEC: human umbilical vein endothelial cell; LRP1: low-density lipoprotein receptor-related protein; MMP: matrix metalloproteinase; HPI-4: hedgehog pathway inhibitor 4; PAI-1: plasminogen activator inhibitor 1; PMA: phorbol 12-myristate-13-acetate; TFPI: tissue factor pathway inhibitor; uPA: urokinase plasminogen activator; uPAR: uPA receptor.

SUBMITTER: Schmidt MCB 

PROVIDER: S-EPMC7527229 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3515366 | biostudies-literature
| S-EPMC10053369 | biostudies-literature
| S-EPMC5702589 | biostudies-literature
| S-EPMC7394702 | biostudies-literature
| S-EPMC6935720 | biostudies-literature
| S-EPMC4524284 | biostudies-literature
| S-EPMC3084669 | biostudies-literature
| S-EPMC6133348 | biostudies-literature
| S-EPMC3407930 | biostudies-literature
| S-EPMC3210814 | biostudies-literature